Publications
- Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)2010 | Second Faculty of Medicine
- Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial) [ISRCTN81331696]2005 | Second Faculty of Medicine, First Faculty of Medicine, Faculty of Physical Education and Sport
- The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction2003 | Second Faculty of Medicine, First Faculty of Medicine, Faculty of Physical Education and Sport
- Predictors of long-term survival in patients treated with targeted temperature management after cardiac arrest2020 | Faculty of Mathematics and Physics
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome2020 | Publication without faculty affiliation
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial2020 | Publication without faculty affiliation
- Pitfalls of anticoagulation therapy in pregnant women with mechanical valve prostheses. The case of two thrombotic events during one pregnancy2019 | Publication without faculty affiliation
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial2019 | Publication without faculty affiliation
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes2019 | Publication without faculty affiliation
- Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial2019 | Publication without faculty affiliation
Loading network view...